{"id":"caivt","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal congestion"},{"rate":null,"effect":"Runny nose"},{"rate":null,"effect":"Sore throat"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CAIVT (Cold-Adapted Influenza Vaccine Trivalent) is a live attenuated influenza vaccine that uses temperature-sensitive, cold-adapted virus strains that replicate efficiently in the cooler upper respiratory tract but are attenuated in the warmer lower respiratory tract and systemic tissues. This approach stimulates both mucosal and systemic immune responses, providing protection against influenza infection while minimizing systemic reactogenicity.","oneSentence":"CAIVT is a live attenuated influenza vaccine designed to provide broad protection against multiple influenza virus strains through intranasal delivery.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:37.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention in pediatric and adult populations"}]},"trialDetails":[{"nctId":"NCT00192322","phase":"PHASE2","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-09","conditions":"Influenza","enrollment":173},{"nctId":"NCT00192309","phase":"PHASE2","title":"Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-09","conditions":"Influenza","enrollment":31},{"nctId":"NCT00192335","phase":"PHASE3","title":"Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2004-07","conditions":"Healthy","enrollment":890}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CAIVT","genericName":"CAIVT","companyName":"MedImmune LLC","companyId":"medimmune-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"CAIVT is a live attenuated influenza vaccine designed to provide broad protection against multiple influenza virus strains through intranasal delivery. Used for Influenza prevention in pediatric and adult populations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}